Summary
We measured the serum concentrations of l,25(OH)2-vitamin D3, 25(OH)-vitamin D3, parathyroid hormone (PTH) in 82 male patients with primary gout whose serum uric acid was significantly higher than that of 41 normal control male subjects (8.8 ± 0.2 vs 5.6 ± 0.2 mg/dL, p < 0.001). The serum l,25(OH)2-vitamin D3 concentration was significantly lower in the patients with gout compared with the control subjects (39.6 ± 1.4 vs 44.8 ± 1.7 pg/mL, p < 0.05), while no differences were observed between the two groups in either the serum concentration of 25(OH)-vitamin D3 or PTH. The administration of uric acid lowering agent to the patients for 1 year caused a significant increase in their serum 1,25(OH)2- vitamin D3 concentration which was associated with a significant decrease in their serum uric acid concentration. In contrast, the serum concentrations of 25(OH)-vitamin D3 and PTH were not affected by these drugs. These results suggest that uric acid per se may directly decrease the serum concentration of l,25(OH)2-vitamin D3 in patients with gout by inhibiting 1 -hydroxylase activity.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Vanholder R, Patel S, Hsu CH:Effect of uric acid on plasma levels of 1,25(OH)2D3 in renal failure. J Am Soc Nephrol 4: 1035–1038, 1993.
Lind L, Hanni A, Lithell H, Hvarfner A, Sorenson OH, Ljunghall S:Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens 8: 894–901, 1995.
Scragg R, Holdaway I, Singh V, Metcalf P, Baker J, Dryson E:Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract 27: 181–188, 1995.
Stamp TCB, Round JM:Seasonal changes in human plasma levels of 25-hydroxyvitamin D. Nature 247: 563–565, 1974.
Kerstetter J, Caballero B, O’Brien K, Wurtrman R, Allen L:Mineral homeostasis in obesity:effect of euglycemic hyperinsulinemia. Metabolism 40: 707–713, 1991.
Liel Y, Ulmer E, Shary J, Hollis BW, Bell NH:Low circulating vitamin D in obesity. Calcif Tissue Int 43: 199–201, 1988.
Scragg R, Holdaway I, Jackson R, Lim T:Plasma 25-hydroxyvitamin D3 and its relation to physical activity and other heart disease risk factors in the general population. Ann Epidemiol 2: 697–703, 1992.
Kokot F, Pietrek J, Srokowska S, et al:25-hydroxyvitamin D in patients with essential hypertension. Clin Nephrol 16: 188–192, 1981.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Takahashi, S., Yamamoto, T., Moriwaki, Y., Tsutsumi, Z., Yamakita, Ji., Higashino, K. (1998). Decreased Serum Concentrations of 1,25(OH)2-Vitamin D3 in Patients with Gout. In: Griesmacher, A., Müller, M.M., Chiba, P. (eds) Purine and Pyrimidine Metabolism in Man IX. Advances in Experimental Medicine and Biology, vol 431. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5381-6_11
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5381-6_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7456-5
Online ISBN: 978-1-4615-5381-6
eBook Packages: Springer Book Archive